HRP20192280T1 - Anti-ceacam6 protutijela i njihova uporaba - Google Patents
Anti-ceacam6 protutijela i njihova uporaba Download PDFInfo
- Publication number
- HRP20192280T1 HRP20192280T1 HRP20192280TT HRP20192280T HRP20192280T1 HR P20192280 T1 HRP20192280 T1 HR P20192280T1 HR P20192280T T HRP20192280T T HR P20192280TT HR P20192280 T HRP20192280 T HR P20192280T HR P20192280 T1 HRP20192280 T1 HR P20192280T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antigen
- chain region
- heavy chain
- light chain
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 239000012634 fragment Substances 0.000 claims 16
- 239000000611 antibody drug conjugate Substances 0.000 claims 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
Claims (17)
1. Izolirano anti-CEACAM6 protutijelo ili njegov ulomak koji veže antigen naznačeno time što sadrži:
i. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:48, H-CDR2 koja obuhvaća SEQ ID NO:49, i H-CDR3 koja obuhvaća SEQ ID NO:50 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:52, L-CDR2 koja obuhvaća SEQ ID NO:53, i L-CDR3 koja obuhvaća SEQ ID NO:54, ili
ii. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:106, H-CDR2 koja obuhvaća SEQ ID NO:107, i H-CDR3 koja obuhvaća SEQ ID NO:108 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:110, L-CDR2 koja obuhvaća SEQ ID NO:111, i L-CDR3 koja obuhvaća SEQ ID NO:112, ili
iii. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:4, H-CDR2 koja obuhvaća SEQ ID NO:5, i H-CDR3 koja obuhvaća SEQ ID NO:6 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:8, L-CDR2 koja obuhvaća SEQ ID NO:9, i L-CDR3 koja obuhvaća SEQ ID NO:10, ili
iv. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:34, H-CDR2 koja obuhvaća SEQ ID NO:35, i H-CDR3 koja obuhvaća SEQ ID NO:36 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:38, L-CDR2 koja obuhvaća SEQ ID NO:39, i L-CDR3 koja obuhvaća SEQ ID NO:40, ili
v. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:120, H-CDR2 koja obuhvaća SEQ ID NO:121, i H-CDR3 koja obuhvaća SEQ ID NO:122 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:124, L-CDR2 koja obuhvaća SEQ ID NO:125, i L-CDR3 koja obuhvaća SEQ ID NO:126, ili
vi. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:24, H-CDR2 koja obuhvaća SEQ ID NO:25, i H-CDR3 koja obuhvaća SEQ ID NO:26 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:28, L-CDR2 koja obuhvaća SEQ ID NO:29, i L-CDR3 koja obuhvaća SEQ ID NO:30, ili
vii. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:76, H-CDR2 koja obuhvaća SEQ ID NO:77, i H-CDR3 koja obuhvaća SEQ ID NO:78 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:80, L-CDR2 koja obuhvaća SEQ ID NO:81, i L-CDR3 koja obuhvaća SEQ ID NO:82, ili
viii. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:134, H-CDR2 koja obuhvaća SEQ ID NO:135, i H-CDR3 koja obuhvaća SEQ ID NO:136 i regiju lakog lanca koje veže antigen koja sadrži L- CDR1 koja obuhvaća SEQ ID NO:138, L-CDR2 koja obuhvaća SEQ ID NO:139, i L-CDR3 koja obuhvaća SEQ ID NO:140, ili
ix. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:148, H-CDR2 koja obuhvaća SEQ ID NO:149, i H-CDR3 koja obuhvaća SEQ ID NO:150 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:152, L-CDR2 koja obuhvaća SEQ ID NO:153, i L-CDR3 koja obuhvaća SEQ ID NO:154, ili
x. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:14, H-CDR2 koja obuhvaća SEQ ID NO:15, i H-CDR3 koja obuhvaća SEQ ID NO:16 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:18, L-CDR2 koja obuhvaća SEQ ID NO:19, i L-CDR3 koja obuhvaća SEQ ID NO:20, ili
xi. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:62, H-CDR2 koja obuhvaća SEQ ID NO:63, i H-CDR3 koja obuhvaća SEQ ID NO:64 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:66, L-CDR2 koja obuhvaća SEQ ID NO:67, i L-CDR3 koja obuhvaća SEQ ID NO:68, ili
xii. regiju teškog lanca koje veže antigen koja sadrži H-CDR1 koja obuhvaća SEQ ID NO:92, H-CDR2 koja obuhvaća SEQ ID NO:93, i H-CDR3 koja obuhvaća SEQ ID NO:94 i regiju lakog lanca koje veže antigen koja sadrži L-CDR1 koja obuhvaća SEQ ID NO:96, L-CDR2 koja obuhvaća SEQ ID NO:97, i L-CDR3 koja obuhvaća SEQ ID NO:98.
2. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 naznačeno time što sadrži:
i. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 47 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 51, ili
ii. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 105 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 109, ili
iii. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 3 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 7, ili
iv. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 33 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 37, ili
v. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 119 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 123, ili
vi. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 23 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 27, ili
vii. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 75 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 79, ili
viii. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 133 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 137, ili
ix. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 147 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 151, ili
x. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 13 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 17, ili
xi. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 61 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 65, ili
xii. varijabilnu sekvencu teškog lanca koju predstavlja SEQ ID NO: 91 i varijabilnu sekvencu lakog lanca koju predstavlja SEQ ID NO: 95.
3. Protutijelo prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što je IgG protutijelo.
4. Protutijelo prema bilo kojem od prethodnih patentnih zahtjeva naznačeno time što sadrži:
i. regiju teškog lanca koja odgovara SEQ ID NO: 57 i regiju lakog lanca koja odgovara SEQ ID NO: 58, ili
ii. regiju teškog lanca koja odgovara SEQ ID NO: 115 i regiju lakog lanca koja odgovara SEQ ID NO: 116, ili
iii. regiju teškog lanca koja odgovara SEQ ID NO: 43 i regiju lakog lanca koja odgovara SEQ ID NO: 44, ili
iv. regiju teškog lanca koja odgovara SEQ ID NO: 129 i regiju lakog lanca koja odgovara SEQ ID NO: 130, ili
v. regiju teškog lanca koja odgovara SEQ ID NO: 85 i regiju lakog lanca koja odgovara SEQ ID NO: 86, ili
vi. regiju teškog lanca koja odgovara SEQ ID NO: 143 i regiju lakog lanca koja odgovara SEQ ID NO: 144, ili
vii. regiju teškog lanca koja odgovara SEQ ID NO: 157 i regiju lakog lanca koja odgovara SEQ ID NO: 158, ili
viii. regiju teškog lanca koja odgovara SEQ ID NO: 71 i regiju lakog lanca koja odgovara SEQ ID NO: 72, ili
ix. regiju teškog lanca koja odgovara SEQ ID NO: 101 i regiju lakog lanca koja odgovara SEQ ID NO: 102.
5. Ulomak koji veže antigen prema patentnim zahtjevima 1 ili 2, naznačen time što je scFv, Fab, Fab' fragment ili F(ab')2 ulomak.
6. Protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što je monoklonsko protutijelo ili ulomak koji veže antigen.
7. Konjugat protutijelo-lijek, naznačen time što sadrži protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6.
8. Izolirana sekvenca nukleinske kiseline naznačena time što kodira protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6.
9. Vektor naznačen time što sadrži sekvencu nukleinske kiseline prema patentnom zahtjevu 8.
10. Izolirana stanica naznačena time što eksprimira protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 i /ili koja sadrži nukleinsku kiselinu prema patentnom zahtjevu 8 ili vektor prema patentnom zahtjevu 9.
11. Izolirana stanica prema patentnom zahtjevu 10, naznačena time što je navedena stanica prokariotska ili eukariotska stanica.
12. Postupak za proizvodnju protutijela ili ulomka koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 naznačen time što obuhvaća kultiviranje stanice prema patentnom zahtjevu 11 i pročišćavanje protutijela ili ulomka koji veže antigen.
13. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 ili konjugat protutijelo-lijek prema patentnom zahtjevu 7 naznačen time što je za upotrebu kao lijek.
14. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 ili konjugat protutijelo-lijek prema patentnom zahtjevu 7 naznačen time što je za upotrebu kao dijagnostičko sredstvo.
15. Protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 ili konjugat protutijelo-lijek prema patentnom zahtjevu 7 naznačen time što je za upotrebu kao lijek za liječenje raka.
16. Farmaceutski pripravak naznačen time što sadrži protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 6 ili konjugat protutijelo-lijek prema patentnom zahtjevu 7.
17. Kombinacija farmaceutskog pripravka prema patentnom zahtjevu 16 ili jednog ili više terapeutski aktivnih spojeva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15160292 | 2015-03-23 | ||
PCT/EP2016/056104 WO2016150899A2 (en) | 2015-03-23 | 2016-03-21 | Anti-ceacam6 antibodies and uses thereof |
EP16713784.3A EP3274370B1 (en) | 2015-03-23 | 2016-03-21 | Anti-ceacam6 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192280T1 true HRP20192280T1 (hr) | 2020-03-06 |
Family
ID=52692556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192280TT HRP20192280T1 (hr) | 2015-03-23 | 2019-12-18 | Anti-ceacam6 protutijela i njihova uporaba |
Country Status (28)
Country | Link |
---|---|
US (3) | US10584167B2 (hr) |
EP (2) | EP3628688A1 (hr) |
JP (2) | JP6815329B2 (hr) |
KR (1) | KR20170128567A (hr) |
CN (1) | CN107743495B (hr) |
AR (1) | AR104047A1 (hr) |
AU (1) | AU2016236270B2 (hr) |
BR (1) | BR112017020373A2 (hr) |
CA (1) | CA2980390A1 (hr) |
CY (1) | CY1122627T1 (hr) |
DK (1) | DK3274370T3 (hr) |
ES (1) | ES2768784T3 (hr) |
HK (1) | HK1246312A1 (hr) |
HR (1) | HRP20192280T1 (hr) |
HU (1) | HUE048111T2 (hr) |
IL (1) | IL254534B (hr) |
LT (1) | LT3274370T (hr) |
MX (1) | MX2017012278A (hr) |
PE (1) | PE20171790A1 (hr) |
PL (1) | PL3274370T3 (hr) |
PT (1) | PT3274370T (hr) |
RS (1) | RS59878B1 (hr) |
RU (1) | RU2739163C2 (hr) |
SG (1) | SG11201707800QA (hr) |
SI (1) | SI3274370T1 (hr) |
TW (1) | TWI719969B (hr) |
WO (1) | WO2016150899A2 (hr) |
ZA (1) | ZA201707138B (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2980390A1 (en) | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
SG11201903178QA (en) | 2016-10-10 | 2019-05-30 | Singhealth Services Pte Ltd | Anti-ceacam6 antibodies and methods of use |
EP3560957A4 (en) | 2016-11-14 | 2020-10-21 | Dinona | ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE |
WO2018128486A1 (ko) * | 2017-01-05 | 2018-07-12 | 한국생명공학연구원 | Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체 |
WO2018157169A1 (en) * | 2017-02-27 | 2018-08-30 | Caerus Therapeutics, Inc. | Antibody constructs and methods of treating cancer |
WO2018200562A1 (en) * | 2017-04-24 | 2018-11-01 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibody agents |
US20200140572A1 (en) * | 2017-05-23 | 2020-05-07 | Kaohsiung Medical University | Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy |
TW201910349A (zh) * | 2017-08-10 | 2019-03-16 | 美商格里佛診斷方法股份有限公司 | 包含重組人類cd38細胞外區域之組合物、方法及/或套組 |
KR102134954B1 (ko) | 2018-01-08 | 2020-07-16 | 충북대학교 산학협력단 | CEACAM6 발현 억제를 위한 siRNA 및 이를 포함하는 선암 치료제 |
EP3752533A4 (en) * | 2018-02-13 | 2021-05-05 | Precision Biologics, Inc. | TREG CELL TARGETING METHODS AND COMPOSITIONS |
TW201938588A (zh) * | 2018-03-13 | 2019-10-01 | 英商塔斯克療法有限公司 | 抗-cd25抗體藥劑 |
KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
US12103974B2 (en) * | 2018-05-23 | 2024-10-01 | Beigene, Ltd. | Anti-OX40 antibodies and methods of use |
US20210221908A1 (en) * | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
KR20210091152A (ko) | 2018-11-14 | 2021-07-21 | 바이엘 악티엔게젤샤프트 | 암의 치료를 위한 항-ceacam6 및 항-pd-1 또는 항-pd-l1 항체의 제약 조합물 |
CA3123735A1 (en) | 2018-12-19 | 2020-06-25 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
AU2020289301A1 (en) * | 2019-06-04 | 2022-01-27 | Biotheus Inc. | CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof |
WO2021178951A1 (en) * | 2020-03-06 | 2021-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor targeted fluorescence guidance for intraoperative margin assessment |
CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
CN112457402B (zh) * | 2020-10-21 | 2022-08-30 | 北京纽安博生物技术有限公司 | 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用 |
WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
KR20240028325A (ko) * | 2020-12-11 | 2024-03-05 | 매터리어 테라퓨틱스 인크. | 체크포인트 억제제와 조합하여 보센탄을 사용하는 암 치료 |
CA3205463A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
CN112521509B (zh) * | 2020-12-23 | 2022-07-08 | 姚雪英 | 一种抗ceacam5人源化抗体、其缀合物及其用途 |
EP4396229A1 (en) | 2021-09-02 | 2024-07-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
CN116196415B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 用于增敏pd-1抗体的混合制剂及其使用方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP2005524379A (ja) | 2001-08-03 | 2005-08-18 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性の増強を伴う抗体グリコシル化改変体 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
PL2380911T3 (pl) | 2003-11-05 | 2018-10-31 | Roche Glycart Ag | Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej |
ES2579836T3 (es) | 2003-11-06 | 2016-08-17 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
IN2012DN01663A (hr) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
HUE049647T2 (hu) | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
US8404812B2 (en) * | 2010-02-26 | 2013-03-26 | Dinona Inc. | Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same |
US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
CA2813133C (en) * | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
BR112014028826B1 (pt) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | Uso de nivolumab ou pembrolizumabe |
US10131712B2 (en) | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CA2980390A1 (en) | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
US11390674B2 (en) | 2016-04-12 | 2022-07-19 | Symphogen A/S | Anti-TIM-3 antibodies and compositions |
JP7267012B2 (ja) | 2016-05-27 | 2023-05-01 | アジェナス インコーポレイテッド | 抗tim-3抗体及びその使用方法 |
JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Tim3に対する抗体およびその使用 |
JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
EP3560957A4 (en) | 2016-11-14 | 2020-10-21 | Dinona | ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE |
BR112019014169A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-tim-3 |
-
2016
- 2016-03-21 CA CA2980390A patent/CA2980390A1/en active Pending
- 2016-03-21 PL PL16713784T patent/PL3274370T3/pl unknown
- 2016-03-21 BR BR112017020373-1A patent/BR112017020373A2/pt not_active IP Right Cessation
- 2016-03-21 DK DK16713784.3T patent/DK3274370T3/da active
- 2016-03-21 CN CN201680024895.XA patent/CN107743495B/zh active Active
- 2016-03-21 EP EP19202632.6A patent/EP3628688A1/en active Pending
- 2016-03-21 HU HUE16713784A patent/HUE048111T2/hu unknown
- 2016-03-21 PT PT167137843T patent/PT3274370T/pt unknown
- 2016-03-21 TW TW105108621A patent/TWI719969B/zh active
- 2016-03-21 ES ES16713784T patent/ES2768784T3/es active Active
- 2016-03-21 SG SG11201707800QA patent/SG11201707800QA/en unknown
- 2016-03-21 PE PE2017001579A patent/PE20171790A1/es unknown
- 2016-03-21 AU AU2016236270A patent/AU2016236270B2/en active Active
- 2016-03-21 RS RS20200132A patent/RS59878B1/sr unknown
- 2016-03-21 SI SI201630585T patent/SI3274370T1/sl unknown
- 2016-03-21 LT LTEP16713784.3T patent/LT3274370T/lt unknown
- 2016-03-21 WO PCT/EP2016/056104 patent/WO2016150899A2/en active Application Filing
- 2016-03-21 RU RU2017137010A patent/RU2739163C2/ru active
- 2016-03-21 EP EP16713784.3A patent/EP3274370B1/en active Active
- 2016-03-21 KR KR1020177029946A patent/KR20170128567A/ko not_active Application Discontinuation
- 2016-03-21 US US15/561,013 patent/US10584167B2/en active Active
- 2016-03-21 MX MX2017012278A patent/MX2017012278A/es active IP Right Grant
- 2016-03-21 JP JP2017549507A patent/JP6815329B2/ja active Active
- 2016-03-22 AR ARP160100772A patent/AR104047A1/es unknown
-
2017
- 2017-09-17 IL IL254534A patent/IL254534B/en unknown
- 2017-10-20 ZA ZA2017/07138A patent/ZA201707138B/en unknown
-
2018
- 2018-05-02 HK HK18105631.4A patent/HK1246312A1/zh unknown
-
2019
- 2019-12-18 HR HRP20192280TT patent/HRP20192280T1/hr unknown
-
2020
- 2020-01-29 US US16/776,329 patent/US11866495B2/en active Active
- 2020-01-29 US US16/776,326 patent/US11773164B2/en active Active
- 2020-02-13 CY CY20201100133T patent/CY1122627T1/el unknown
- 2020-12-22 JP JP2020212437A patent/JP7185379B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
IL265434B1 (en) | Anti-CD27 antibodies | |
HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
HRP20211935T1 (hr) | Protutijela anti-alfa-sinuklein i njihove uporabe | |
RU2019118359A (ru) | Антитело к cd73 человека | |
JP2018510636A5 (hr) | ||
RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
JP2018527919A5 (hr) | ||
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
JP2015533795A5 (hr) | ||
HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
JP2012116856A5 (hr) | ||
PE20142041A1 (es) | Anticuerpos anti-il-36r | |
JP2013198490A5 (hr) | ||
PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos |